43 Result(s)
within
Kong** Wu
Cancer Research
Hematology
-
Article
Open AccessDACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells
Renal cell carcinoma (RCC) is a complex with diverse biological characteristics and distinct molecular signature. New target therapies to molecules that drive RCC initiation and progression have achieved promi...
-
Article
Open AccessNotch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Through epithelial-mesenchymal transition (EMT), cancer cells acquire enhanced ability of migration and invasion, stem cell like characteristics and therapeutic resistance. Notch signaling regulates cell-cell ...
-
Article
Open AccessNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor...
-
Article
Open AccessEmerging roles of Nrf2 signal in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) causes considerable mortality in the world. Owing to molecular biological progress, treatments in adenocarcinoma have evolved revolutionarily while those in squamous lung can...
-
Article
Open AccessModification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer
The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-assoc...
-
Article
Open AccessThe expression profile and clinic significance of the SIX family in non-small cell lung cancer
The SIX family homeobox genes have been demonstrated to be involved in the tumor initiation and progression, but their clinicopathological features and prognostic values in non-small cell lung cancer (NSCLC) h...
-
Article
Open AccessProstate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue
The causative role of the pro-inflammatory cytokine IL-6 in prostate cancer progression has been well established at molecular level. However, whether and how IL-6 may play a role in prostate cancer risk and d...
-
Article
Open AccessChimeric antigen receptor T cells: a novel therapy for solid tumors
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...
-
Article
Open AccessRecent advances of highly selective CDK4/6 inhibitors in breast cancer
Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...
-
Article
Open AccessRecent advances of bispecific antibodies in solid tumors
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and mo...
-
Article
Open AccessDevelopment and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...
-
Article
Open AccessGut microbiome modulates efficacy of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic...
-
Article
Open AccessDACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h...
-
Article
Open AccessOrganoid technology and applications in cancer research
During the past decade, the three-dimensional organoid technology has sprung up and become more and more popular among researchers. Organoids are the miniatures of in vivo tissues and organs, and faithfully re...
-
Article
Open AccessThe role of neoantigen in immune checkpoint blockade therapy
Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...
-
Article
Open AccessOrganoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...
-
Article
Open AccessRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, includin...
-
Article
Open AccessActivating cGAS-STING pathway for the optimal effect of cancer immunotherapy
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor mass. Cancer immunotherapy eradicates tumor cells by enhancing multiple steps in ...
-
Article
Open AccessProspects for combining immune checkpoint blockade with PARP inhibition
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble. This impaired anti-cance...
-
Article
Open AccessThe efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...
